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Abstract
Using genome-wide data from 253,288 individuals, we identified 697 variants at genome-wide 
significance that together explain one-fifth of heritability for adult height. By testing different 
numbers of variants in independent studies, we show that the most strongly associated ~2,000, 
~3,700 and ~9,500 SNPs explained ~21%, ~24% and ~29% of phenotypic variance. Furthermore, 
all common variants together captured the majority (60%) of heritability. The 697 variants 
clustered in 423 loci enriched for genes, pathways, and tissue-types known to be involved in 
growth and together implicated genes and pathways not highlighted in earlier efforts, such as 
signaling by fibroblast growth factors, WNT/beta-catenin, and chondroitin sulfate-related genes. 
We identified several genes and pathways not previously connected with human skeletal growth, 
including mTOR, osteoglycin and binding of hyaluronic acid. Our results indicate a genetic 
architecture for human height that is characterized by a very large but finite number (thousands) of 
causal variants.
Height is a classical polygenic trait that has provided general insights into the genetic 
architecture of common human traits and diseases, and into the prospects and challenges of 
different methods used to identify genetic risk factors. Studies consistently estimate that the 
additive genetic contribution to normal variation in adult height (“narrow sense heritability”) 
is approximately 80%1-3. Previous analysis of genome-wide association studies (GWAS) of 
adult height showed that common variants together account for 50% of this heritable 
contribution to height variation4,5. The most recent GWAS of adult height identified 180 
loci, which together highlighted many genes relevant to human skeletal growth that had not 
been implicated in previous studies6. Common variants in these loci, however, only 
accounted for 10% of the phenotypic variation (~12% of heritability). Here, we report 
results from a GWAS meta-analysis of adult height in 253,288 individuals of European 
ancestry. We show that additive contributions of fewer than 10,000 SNPs (at P<5×10−3) can 
account for 36% of the heritability of adult height. Variants reaching genome-wide 
significance (P<5×10−8) in this larger study (697 SNPs) clustered in loci, were substantially 
enriched for regulatory variants, and implicated multiple known and previously unknown 
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genes and pathways relevant to growth. More broadly, our results provide evidence that 
increasing GWAS sample sizes to the order of 100,000s, now plausible for many common 
traits, will likely continue to identify the variants and loci that close the “missing 
heritability” gap, whilst improving knowledge of the biology of those traits.
Results
The overall analysis strategy is illustrated in Supplementary Figure 1. We first performed a 
GWAS meta-analysis of adult height using summary statistics from 79 studies consisting of 
253,288 individuals of European ancestry (Online Methods). We identified 697 SNPs that 
reached genome-wide significance (P<5×10−8) using an approximate conditional and joint 
multiple-SNP (COJO) analysis7 in GCTA8 (Online Methods) which takes linkage 
disequilibrium (LD) between SNPs into account (Supplementary Table 1; Supplementary 
Figs. 2-3). The 697 SNPs clustered in 423 loci, with a locus defined as one or multiple 
jointly associated SNPs located within ±1Mb of each other. Most of these 697 SNPs are 
uncorrelated although those in close physical proximity (e.g. < 1Mb) may be in partial LD 
(see Supplementary Table 1 for LD between adjacent pairs of the 697 SNPs). The clustering 
of signals was non-random (empirical enrichment of 1.4 fold, P<1×10−4) with 90, 26 and 31 
loci containing 2, 3 and ≥ 4 signals respectively, (Supplementary Note and Supplementary 
Tables 1 and 2). We observed strong evidence of clustering of association signals within loci 
across a range of locus sizes, from 100kb to 1.25Mb, but the clustering was almost entirely 
driven by variants within 250kb of index SNPs (Supplementary Note and Supplementary 
Table 2). As shown in Figure 1 and Supplementary Figure 4, in some loci, multiple signals 
cluster tightly around a single gene, whereas in other cases, the clustering of associated 
variants is likely due to multiple different height-related genes being in close proximity.
Of the 697 SNPs, 403 were represented on the Metabochip array9. Using data from 80,067 
individuals genotyped on the Metabochip array from 37 independent studies, we observed 
very strong evidence of concordance of effect sizes between the Metabochip and GWAS 
samples (P = 1.9×10−160); and >99% of variants were directionally consistent between 
Metabochip and GWAS (Online Methods, Supplementary Note, and Supplementary Table 
3).
We observed a large genome-wide ‘inflation’ factor of the test statistic for association even 
after we corrected each study’s test statistics by its individual inflation factor (single λGC = 
1.94). At least two phenomena could have contributed to this observation. First, as described 
previously10, highly polygenic models of inheritance are expected to increase the genomic 
inflation factor to levels comparable to what we observe. Second, height is particularly 
susceptible to confounding by population ancestry (stratification), which can also lead to 
inflation of the test statistics. We addressed these possibilities by comparing our results with 
those obtained using more stringent corrections for stratification (linear mixed models), and 
with results obtained in subsets of studies in which a purely family-based analysis was 
feasible, and by performing a within-family prediction analysis which partitioned the 
variance in the genetic predictor into the contributions of true associations and population 
stratification.
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Our linear mixed model (LMM) analyses, performed in a subset of 15 individual studies 
comprising 59,380 individuals, provided strong evidence that the inflated statistics were 
driven predominantly by the highly polygenic nature of the trait. This approach utilizes a 
genomic relationship matrix (GRM) calculated through genome-wide SNP data to correct 
for distant relatedness between all pairs of individuals within a study. This resulted in a 
single λGC of 1.20. This value was entirely consistent with the single λGC of 1.20 obtained 
from the standard GWAS analysis of the same individuals and a single λGC of 1.94 obtained 
from the full 253,288 individuals (Supplementary Table 4). Because this approach may be 
overly conservative for a strongly genetic and highly polygenic trait, each study additionally 
repeated the analyses for each chromosome using a GRM generated from the remaining 21 
chromosomes, or in the case of the largest study (WGHS) repeating the analysis for all odd 
numbered chromosomes using a GRM generated from the even numbered chromosomes and 
vice versa. The single λGC inflation factor for this analysis, 1.23, was also entirely consistent 
with the standard GWAS results (Online Methods, Supplementary Note, and Supplementary 
Table 4).
Our family based analyses also provided strong evidence that the inflated statistics are 
driven predominantly by the highly polygenic nature of height. We assessed whether 
variants that reached genome-wide significance after single GC correction replicated in 
family-based analyses of up to 25,849 samples (effective sample size 14,963, using methods 
that are immune to stratification (Online Methods, Supplementary Note, and Supplementary 
Tables 5 and 6). We identified genome-wide significant associations from a meta-analysis 
that excluded the family-based samples, and tested these associations for replication in the 
family-based samples; a lower rate of replication than expected could be due to inflation of 
effect sizes in the discovery sample from the “winner’s curse” and/or stratification. Of 416 
genome-wide significant SNPs representing multiple signals selected after exclusion of 
family-based studies, 371 SNPs had a consistent direction of effect (compared with 208 
expected by chance, and 400 expected in the absence of any inflation of estimated effect 
sizes), and 142 replicated with P<0.05 (compared with 21 expected by chance, and 210 
expected in the absence of effect size inflation; Supplementary Table 5). These analyses 
(particularly the directional consistency) shows that most of the loci represent true 
associations, but also shows that there is a modest inflation in the effect size estimates, due 
to stratification and/or the winner’s curse. To distinguish between these possibilities, we 
repeated this analysis, substituting for the family-based samples a random set of studies with 
similar total effective sample size. The number of replicating loci was only slightly lower in 
the family-based cohorts than in the random samples (Supplementary Table 5, 12-17 fewer 
replications attributable to stratification at different P-value thresholds). This indicates that 
most of the modest inflation in effect estimates is due to the winner’s curse, that a small 
amount of inflation is due to residual stratification, and that few (upper limit ~15-25; 
Supplementary Note and Supplementary Table 5) if any of the loci that reach genome-wide 
significance after single GC correction are likely to be complete false positives due to 
stratification (that is, no real association whatsoever with height).
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Variance explained by SNPs at different significance levels
Having established that single GC correction is sufficient to identify SNPs that are likely to 
be truly associated with height, we next performed a series of analyses using GWAS data 
from five independent validation studies to quantify the fraction of phenotypic variance 
explained by SNPs selected from the GCTA-COJO analyses7 of the meta-analysis data, 
which excluded data from the validation studies, at a range of statistical thresholds, and to 
quantify the accuracy of predicting height using these selected SNPs (Online Methods). We 
first developed a new method that uses within-family prediction to partition the variance of 
the SNP-based predictor into components due to real SNP effects, errors in estimating SNP 
effects, and population stratification (Online Methods), and applied the method to data on 
full-sib pairs from three of the five validation studies (Online Methods). Consistently across 
the three studies, all the partitioned variance components increased as a less stringent 
significance level was used for SNP selection in the discovery sample and the error variance 
increased more dramatically than the genetic variance when more SNPs selected at a less 
significance level were included in the predictor (Fig. 2a-c). We demonstrated the 
partitioning of variance due to population stratification by the within-family prediction 
analyses with and without adjusting for principal components (PCs) (Supplementary Fig. 5). 
The results again confirmed that the impact of population stratification on the top associated 
SNPs was minor and demonstrated that the variation in the predictor due to true SNP effect, 
estimation error and population stratification was quantifiable. We next inferred, using these 
partitioned variance components from the within-family prediction analysis, how well 
different selected sets of SNPs would predict height in independent samples. We showed 
that the observed prediction accuracy (squared correlation between phenotype and predictor, 
R2) in five different population-based cohorts was highly consistent with the values inferred 
from the within-family based analyses, with prediction accuracy peaking at ~17% using the 
~1,900 SNPs reaching P<5×10−5 (Fig. 2d). Finally we estimated variance explained by the 
selected SNPs in population-based studies using the GCTA-GREML method4,8 (Fig. 2e). 
The results showed that ~670 SNPs at P<5×10−8 and ~9,500 SNPs at P<5×10−3 captured 
~16% and ~29% of phenotypic variance respectively (Table 1), which was also consistent 
with the estimates inferred from the within-family prediction analysis. As shown in equation 
[19], prediction R2 is not equal to the variance explained but a function of the variance of 
true SNP effects and the error variance in estimating SNP effects, in the absence of 
population structure. This is demonstrated in Figure 2, where at thresholds below genome-
wide significance, variance explained is higher than the prediction accuracy, because the 
latter is deflated both by imprecise estimates of effect sizes (estimation errors) and by 
inclusion of SNPs that are not associated with height. The estimate of variance explained by 
all the HapMap3 (ref. 11) SNPs without SNP selection was ~50% (Table 1), consistent with 
previous estimates4,5. Thus, a group of ~9,500 SNPs (representing <1% of common SNPs) 
selected at P<5×10−3, explained ~29% of phenotypic variance. Since ~50% of phenotypic 
variance is explained by all common SNPs, the selected set of SNPs, despite being limited to 
<1% of common SNPs, accounts for the majority of variance attributable to all common 
SNPs (29/50 ~ 60%). This set of ~9,500 SNPs strongly clustered with the newly established 
height loci: 1,704 (19%) variants were located within 250kb of one of the 697 genome-wide 
associated SNPs, suggesting that a substantial fraction of “missing heritability” is within 
already identified loci. This clustering of additional variants within identified loci was 
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confirmed in a parallel analysis based on two left-out studies where we observed that SNPs 
in closer physical proximity with the top associated SNPs explained disproportionally more 
variance (Online Methods and Supplementary Fig. 6).
Larger GWAS identifies new biologically relevant genes and pathways
Having shown that ~1% of variants can account for the majority of heritability attributable 
to common variation, we next considered whether the expanded set of height-associated 
variants could be used to identify the genomic features and biological pathways of most 
relevance to normal variation in adult height. To test whether our GWAS could implicate 
new biology, we used established and novel approaches to test whether the height-associated 
loci were enriched for functionally relevant variants, genes, pathways, and tissues.
As with the 180 variants identified in our previous analysis, the 697 variants were non-
randomly distributed with respect to functional and putatively functional regions of the 
genome (Online Methods). We observed that height associated variants were enriched for 
non-synonymous SNPs (nsSNPs) (empirical enrichment of 1.2 fold, P=0.02), cis-regulatory 
effects in blood (empirical enrichment of 1.5 fold, P=0.03), a curated list of genes that 
underlie monogenic syndromes of abnormal skeletal growth12 (empirical enrichment 1.4 
fold, P=0.013), associations with apparently unrelated complex traits in the NHGRI GWAS 
catalog (empirical enrichment 2.6 fold, P<1×10−4) and functional chromatin annotations in 
multiple tissues and cell types (empirical enrichment 1.8 fold, P<1×10−3) (Supplementary 
Note and Supplementary Tables 7-11).
The greater resolution of height associated variants provided by increased sample size, 
combined with improved gene prioritization and gene set enrichment approaches, identified 
multiple new tissues, gene sets and specific genes that are highly likely to be involved in the 
biology of skeletal growth. Specifically, using a variety of established and novel pathway 
methods, we identified ~3 times as many enriched pathways and prioritized ~5 times as 
many genes (including genes newly prioritized in previously identified loci) compared to 
results derived from identical pathway methods to the previous GWAS of 133,000 
individuals (Table 2).
We first focused on existing pathway and gene prioritization methods: (1) MAGENTA13, a 
method designed to identify gene sets enriched in GWAS data, and (2) GRAIL14, which 
uses published literature to highlight connections between likely relevant genes within 
GWAS loci. As expected, the GRAIL and MAGENTA analyses confirmed several 
previously identified gene sets and pathways clearly relevant to skeletal growth, but in the 
larger sample they also provided evidence for additional known and novel genes, gene sets 
and protein complexes not identified in our previous smaller study (for example, FGF 
signaling, WNT signaling, osteoglycin, and other genes related to bone or cartilage 
development) (Supplementary Tables 12-13 and Supplementary Fig. 7).
To obtain more detailed insight into height biology, we applied DEPICT, a novel data-
driven integrative method that uses gene sets reconstituted based on large scale expression 
data to prioritize genes and gene sets, and also to identify tissues enriched in highly 
expressed genes from associated loci (Pers et al. in preparation; Online Methods and 
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Supplementary Note). The DEPICT analysis highlighted 2,330 reconstituted gene sets (after 
pruning for high levels of redundancy). These gene sets both confirmed and extended the 
MAGENTA and GRAIL findings, and identified novel pathways not identified in our 
previous height GWAS (for example regulation of beta-catenin, biology related to 
glycosaminoglycans such as chondroitin sulfate and hyaluronic acid, and mTOR signaling) 
(Supplementary Table 14). Gene sets identified based on 327 strictly novel height variants 
(>1Mb from the 180 known variants loci) highly resembled gene sets highlighted by the 
already known 180 loci (Spearman’s rank correlation coefficient between gene set 
enrichment Z-scores r=0.91, P=2×10−16). Thus, the variants discovered through increased 
sample size continued to highlight specific and relevant growth-associated gene sets, while 
the combined analysis of both old and new loci provided the additional power needed to 
identify new gene sets (Table 3 and Supplementary Table 14).
The DEPICT analysis also prioritized tissues and individual genes. We found that genes 
within associated height loci were enriched for expression in tissues related to chondrocytes 
(cartilage, joint capsule, synovial membrane, and joints; P<5.5×10−9, FDR<0.001), and 
other musculoskeletal, cardiovascular, and endocrine tissue-types (FDR<0.05) (Fig. 3; 
Supplementary Fig. 8; Supplementary Table 15). We also showed that a subset of the 697 
height associated SNPs that represented lead cis-eQTLs in blood defined 75 genes that were 
collectively enriched for expression in cartilage (P=0.008) (Supplementary Note and 
Supplementary Table 8).
We used DEPICT to prioritize 649 genes (at FDR<0.05) within height-associated loci (Table 
3 and Supplementary Table 16). Of these 649 genes, 202 genes (31%) were either 
significant in the GRAIL analysis (Supplementary Tables 13 and 16) and/or overlapped with 
a list of abnormal skeletal growth syndromes that we assembled from the OMIM database12 
(n=40; Supplementary Tables 9 and 16). Many other newly prioritized genes had additional 
supporting evidence (Supplementary Table 16), including specific expression in the growth 
plate12, and/or connections to relevant pathways (for example: GLI2 and LAMA5 [hedgehog 
signaling]; FRS2 [FGF signaling]; AXIN2, NFATC1, CTNNB1, FBXW11, WNT4, WNT5A 
and VANGL2 [WNT/beta-catenin signaling]; SMAD3 and MTOR [TGF-beta and/or mTOR 
signaling]; WWP2/miR140, IBSP, SHOX2 and SP3 [required in mice for proper bone and 
cartilage formation]; CHYS1, DSE and PCOLCE2 [glycosaminoglycan/collagen 
metabolism]; SCARA3, COPZ2, TBX18, CRISPLD1 and SLIT3 [differential expression in 
growth plate and predicted to be in highly relevant pathways]).
DEPICT also prioritizes genes that are new candidates for playing a role in skeletal growth. 
The genes newly and strongly implicated in this study included not only genes with obvious 
relationships to skeletal biology, such as SOX5 and collagen genes, but also genes that have 
no clear published connection to skeletal growth, and likely represent as yet unknown 
biology (Table 3 and Supplementary Table 16). DEPICT strongly prioritized genes that do 
not have published annotations related to growth-related pathways but are predicted to be in 
gene sets that are both enriched in the associated loci and clearly connected to growth. These 
include genes newly predicted to be in pathways related to cartilage or bone development 
(FAM101A, CRISPLD1 and the noncoding RNA LINC00476), collagen or extracellular 
matrix (GLT8D2, CCDC3, and ZCCHC24), histone demethylation (ATAD2B and TSTD2) 
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and other genes predicted to have skeletal phenotypes but not currently annotated as 
belonging to relevant pathways (ARSJ, PSKH1, COPZ2, ADAMTS17 and the microRNA 
cluster MIR17HG). Of note, mutations in both ADAMTS17 and MIR17HG have been 
identified as causes of syndromic short stature in humans15,16.
As suggested by the prioritization of ADAMTS17 and MIR17HG, it is possible that some of 
the newly highlighted genes may also underlie new syndromes of abnormal skeletal growth. 
As a further proof of principle, the second entry on our list of prioritized genes (Table 3 and 
Supplementary Table 16), CHSY1, was not a known monogenic gene in the OMIM 
database12 when we assembled our list, but mutations in this gene have since been shown to 
cause a syndrome including brachydactyly and short stature17,18. Thus, the novel DEPICT 
method, applied to the larger GWAS data set, not only identified similar biology to GRAIL 
and MAGENTA but also implicated a large number of additional genes, gene sets and 
pathways that that are likely important in skeletal biology and human growth.
Discussion
By performing a large GWAS study on adult height, a highly heritable polygenic trait, we 
have provided answers to several current questions of relevance to the genetic study of 
polygenic diseases and traits. First, we showed that by conducting larger GWAS, we can 
identify SNPs that explain a substantial proportion of the heritability attributable to common 
variants. As hypothesized by Yang et al. (2010), the heritability directly accounted for by 
variants identified by GWAS and inferred by whole-genome estimation approaches are 
converging with increasing sample size. The variance explained by genome-wide significant 
SNPs has increased from 3-5% with discovery samples of ~25,000 (ref. 19) to 10% with a 
discovery sample size of ~130,000 (ref. 6) to 16% with a discovery sample size of 250,000 
(this study), and the variance explained from all captured common SNPs is ~50%4,5. The 
variance explained by genome-wide significant SNPs on a chromosome is also proportional 
to its length, consistent with the conclusion made by Yang et al.5 using all SNPs 
(Supplementary Fig. 9). Our new results show that ~21%, ~24% and ~29% of phenotypic 
variance in independent validation samples is captured by the best ~2,000, ~3,700 and 
~9,500 SNPs respectively selected in the discovery samples (Table 1), and that the 
correlation between actual and predicted height in independent samples from the same 
population has increased to 0.41 (maximum prediction R2 = 0.412 = 0.17, Fig. 2d). The 
results are consistent with a genetic architecture for human height that is characterized by a 
very large but finite number (thousands) of causal variants, located throughout the genome 
but clustered in both a biological and genomic manner. Such a genetic architecture may be 
described as pseudo-infinitesimal, and may characterize many other polygenic traits and 
diseases. There is also strong evidence of multiple alleles at the same locus segregating in 
the population and for associated loci to overlap with Mendelian forms, suggesting a large 
but finite genomic mutational target for height, and effect sizes ranging from minute 
(<1mm; ~0.01 SDs) to gigantic (>300mm; >3 SDs, in the case of monogenic mutations).
It has been argued that the biological information emerging from GWA studies will become 
less relevant as sample sizes increase, because as thousands of associated variants are 
discovered, the range of implicated genes and pathways will lose specificity and cover 
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essentially the entire genome20. If this were the case, then increasing sample sizes would not 
help to prioritize follow up studies aimed at identifying and understanding new biology, and 
the associated loci would blanket the entire genome. Our study provides strong evidence to 
the contrary: the identification of many 100’s and even 1000’s of associated variants can 
continue to provide biologically relevant information. In other words, the variants identified 
in larger sample sizes both display a stronger enrichment of pathways clearly relevant to 
skeletal growth and prioritize many additional new and relevant genes. Furthermore, the 
associated variants are often non-randomly and tightly clustered (typically separated by 
<250 kb), resulting in the frequent presence of multiple associated variants in a locus. The 
observations that genes and especially pathways are now beginning to be implicated by 
multiple variants suggests that the larger set of results retain biological specificity but that at 
some point, a new set of associated variants will largely highlight the same genes, pathways 
and biological mechanisms as have already been seen. This endpoint (which we have not 
clearly reached for height) could be considered analogous to reaching “saturation” in model 
organism mutagenesis screens, where new alleles typically map to previously identified 
genes21.
We have identified a large number of gene sets and pathways that are enriched for 
associations with height. Although the number of gene sets and pathways is large, many are 
overlapping and likely represent multiple annotations of a much smaller set of core 
biological mechanisms. We also highlight individual genes within associated loci as being 
relevant to skeletal growth, including candidates for contributing to syndromes of abnormal 
skeletal growth; for example, we strongly implicated CHSY1, recently identified as an 
underlying cause of a monogenic syndrome with short stature and brachydactyly17,18. The 
lists of prioritized genes and pathways should therefore provide a rich trove of data for 
future studies of skeletal growth; to facilitate such studies, we have made our results 
(including genome-wide association results and complete list of highlighted genes and 
pathways) publicly available. Based on the results of large genetic studies of height, we 
anticipate that increasing the number of associated loci for other traits and diseases could 
yield similarly rich lists that would generate new biological hypotheses and motivate future 
research into the basis of human biology and disease.
ONLINE METHODS
Genome-wide association study meta-analysis
We combined height summary association statistics from 79 genome-wide association 
(GWA) studies in a meta-analysis of 253,288 individuals using the same methods and 
studies as previously described6 and additional studies as described in Supplementary 
Tables 17-19. A total of 2,550,858 autosomal SNPs were meta-analyzed using inverse-
variance fixed effects method using METAL22.
GCTA-COJO: conditional and joint multiple SNPs analysis
We used GCTA-COJO analysis7,8 to select the top associated SNPs. This method uses the 
summary statistics from the meta-analysis and LD correlations between SNPs estimated 
from a reference sample to perform a conditional association analysis7. The method starts 
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with an initial model of the SNP that shows the strongest evidence of association across the 
whole genome. It then implements the association analysis conditioning on the selected 
SNP(s) to search for the top SNPs one-by-one iteratively via a stepwise model selection 
procedure until no SNP has a conditional P-value that passes the significance level. Finally, 
all the selected SNPs are fitted jointly in the model for effect size estimation. We used 6,654 
unrelated individuals from the ARIC cohort as the reference sample for LD estimation. 
There were ~3.0M SNPs included in the original meta-analysis. We included in this analysis 
only the SNPs (~2.48M) on HapMap2 and with sample size > 50,000. We used the genome-
wide significance level P<5×10−8 (as reported in Supplementary Table 1).
Metabochip replication
We combined height summary association statistics from 37 independent studies genotyped 
using Illumina’s Metabochip array9 in a meta-analysis of 80,067 individuals of European 
ancestry (Supplementary Tables 20-22). Each study tested association between each 
genotyped SNP and the same QC procedures, height transformations, adjustment, and 
inheritance model as described for the GWA analysis. Genomic control correction was 
applied to results for each study prior to meta-analysis, using a set of 4,427 SNPs associated 
with QT interval to control study-specific inflation factors. We used the inverse-variance 
fixed effects meta-analysis method.
Validation – linear mixed model (LMM) based association analysis
Each of 15 studies (59,380 individuals) used genome-wide SNP information to calculate a 
genomic relationship matrix (GRM) for all pairs of individuals and used this to correct 
association statistics for cryptic relatedness and population stratification. Each study used a 
linear mixed model as implemented in the software EMMAX23. Meta-analysis was 
performed as described for the standard GWAS and using a single GC correction. Each 
study additionally repeated the analyses for each chromosome using a GRM generated from 
the remaining 21 chromosomes, or in the case of the largest study (WGHS) repeating the 
analysis for all odd numbered chromosomes using a GRM generated from the even 
numbered chromosomes and vice versa. Each study then combined association results from 
the 22 or 2 parts of the genome into one set of data and we repeated the single GC meta-
analysis.
Validation – within family (transmission) association analyses
A pure transmission based analysis was performed in seven cohorts for SNPs representing 
416 signals of association (Supplementary Note), selected after repeating meta-analysis 
excluding these studies, with single GC correction. Filtering of low imputation quality SNPs 
in the studies was followed by inverse variance method of meta-analysis of the family based 
results. Because of the presence of related individuals, family based studies have lower 
power at a given sample size. For each study, we calculated the effective sample size (the 
size of a sample of unrelated individuals that would have the equivalent power; see 
Supplementary Note and Winkler et al. 24). Estimation of winner’s curse in our data set was 
performed by repeating the meta-analysis excluding either the family-based studies or 
excluding random sets of studies from GIANT matched by effective sample size to the 
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family based studies. Independent genome-wide significant loci were selected from each 
meta-analysis. Power for replication in the excluded samples was estimated at different P-
value thresholds and the deficit in replications (number of replications expected minus 
number observed) was calculated. The contribution of the winner’s curse to the deficit in 
replications was estimated as the average deficit across the three sets of random non-family-
based cohorts. By subtracting this from the deficit observed for the family-based cohorts, we 
estimated the lack of replication that could be attributed to stratification (either inflation of 
effect size for true associations, or false positive associations).
Variance and heritability explained
We used GCTA-COJO analysis (Online Methods) to select the top associated SNPs at a 
range of stringent significance levels (5×10−3, 5×10−4, 5×10−5, …, 5×10−8) for estimation 
and prediction analyses. We then quantified the variance explained by those selected SNPs 
using a three-stage analysis, i.e. within-family prediction, GCTA-GREML analysis and 
population based prediction, in five validation studies (B-PROOF, FRAM, QIMR, 
TwinGene and WTCCC-T2D). To avoid sample overlap, we repeated the main GWAS 
meta-analysis and the multiple-SNP analysis five times, each time excluding one of the five 
validation studies. This approach ensured complete independence between data used to 
discover SNPs, and data used to estimate how much variance in height these SNPs explained 
and how well they predicted height. For the within-family prediction analyses, we selected 
1,622, 2,758 and 1,597 pairs of full sibs from the QIMR, TwinGene and FRAM cohorts, 
respectively, with one sib pair per family. For the whole-genome estimation and prediction 
analyses, we used GCTA-GRM8 to estimate the genetic relatedness between individuals and 
selected unrelated individuals with pairwise genetic relatedness <0.025 in each of the five 
studies, i.e. B-PROOF (n = 2,555), FRAM (n = 1,145), QIMR (n = 3,627), TwinGene (n = 
5,668) and WTCCC-T2D (n = 1,914).
Within-family prediction analysis
We used the SNPs selected from GCTA-COJO analysis to create a genetic predictor (also 
called “genetic profile score”) for each of all the full sibs using PLINK25. We then adjusted 
the genetic predictor by the first 20 principal components (PCs) generated from the principal 
component analysis (PCA)26. By comparing the predictors within and between families, we 
partitioned the variance in the predictor analysis into components due to real SNP effects 
(Vg), errors in estimating SNP effects (Ve), and population structure (Cg + Ce), as described 
in the Online Methods below.
We calculated the weighted average of each of the four (co)variance components over the 
three cohorts by their sample size, i.e. Σi (Vg(i) ni)/Σi (ni) with the subscript i indicating the 
cohort and n being the sample size. From the results of these partitioning analyses within 
families we can infer what the prediction R2 (Equation 19 in Online Methods below) and 
what the proportion of variance explained by SNPs (i.e. Vg/VP with VP being the phenotypic 
variance) would be in a sample of unrelated individuals when using the same set of SNPs. 
We then tested these inferred values in unrelated samples.
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GCTA-GREML analysis
We performed the GREML analysis4 in GCTA8 to estimate the variance explained by the 
selected SNPs (h2g) in each of the five validation studies. This method fits the effects of a 
set of SNPs simultaneously in a model as random effects and estimates the genetic variance 
captured by all the fitted SNPs without testing the significance of association of any single 
SNPs. We combined the estimates of h2g from the five studies by the inverse-variance 
approach, i.e. .
Population-based prediction analysis
We created a genetic predictor using the selected SNPs for the unrelated individuals in each 
of the five validation studies. We then calculated the squared correlation (R2) between 
phenotype and predictor in each validation study, and calculated the weighted average of the 
prediction R2 by the sample size across the five studies, i.e. .
Theory and method to partition the variance in a genetic predictor
Under the assumption of an additive genetic model, the phenotype of a quantitative trait can 
be written as
[1]
where y is the trait phenotype, g is the total genetic effect of all SNPs, x is an indicator 
variable for SNP genotypes, b is the SNP effect, and ε is the residual.
From this model, the additive genetic variance is
[2]
with the first component being the expected value of additive genetic variance under linkage 
equilibrium (LE) and second component being the deviation from the expected value could 
be caused by linkage disequilibrium (LD), population structure or selection27.
Considering a pair of full siblings in a family, the additive genetic covariance between the 
sibs is
[3]
For full sibs,
 for SNPs that are in LD, and 
 for SNPs that are not in LD (as 
shown by both empirical and simulation results).
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Let |(SNPs are in LD), and 
|(SNPs are not in LD but correlated due to population 
structure)
Therefore, the genetic variance is
[4]
The genetic covariance between a pair of full-sibs is
[5]
If we take a set of SNPs with their effects estimated from GCTA-COJO analysis (Online 
Methods), and create a predictor using these SNPs in an independent validation sample, we 
can write the predictor as
[6]
where  is the estimate of b with  with e being the error in estimating b.
If we assume b and e are independent and denote  and 
, the variance of the predictor is
[7]
The covariance between the predictors of a pair of full-sibs is
[8]
The covariance between the true phenotype and the predictor of a same individual is
[9]
The covariance between the true phenotype of one sib and the predictor of the other sib is
[10]
If we define  and Δy = y1 − y2,
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[11]
[12]
We therefore can calculate these four parameters as
[13]
[14]
[15]
[16]
where Vg can be interpreted as the variance explained by real SNP effects, Cg is the 
covariance between predictors attributed to the real effects of SNPs that are not in LD but 
correlated due to population stratification, Ve is the accumulated variance due to the errors in 
estimating SNP effects, and Ce is the covariance between predictors attributed to errors in 
estimating the effects of SNPs that are correlated due to population stratification.
To assess the prediction accuracy, we usually perform a regression analysis of the real 
phenotype against the predictor, i.e.
[17]
so that the regression slope is actually
[18]
with the regression R2 being
[19]
In the absence of population structure,
[20]
Variance explained by SNPs in proximity to the top associated SNPs
We performed analyses to quantify the variance explained by SNPs in close physical 
proximity to the top associated SNPs in 9,500 unrelated individuals (pairwise genetic 
relatedness < 0.025) from a combined dataset of the QIMR and TwinGene cohorts. As in 
previous analyses, to avoid sample overlap between discovery and validation studies, we 
repeated the discovery meta-analysis excluding the QIMR and TwinGene cohorts, and 
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identified 643 genome-wide significant SNPs from the GCTA-COJO analysis of the 
summary statistics using ARIC data for LD estimation. We used GCTA-GREML analysis4,8 
to quantify the phenotypic variance explained by all the common SNPs (MAF > 0.01) within 
100Kb, 500Kb or 1Mb of the 643 genome-wide significant SNPs. We show in 
Supplementary Figure 6a that there are 104K, 423K and 745K SNPs within 100Kb, 500Kb 
and 1Mb of the top associated SNPs, which explain 20.8% (s.e. = 1.3%), 25.7% (s.e. = 
1.8%) and 29.5% (s.e. = 2.2%) of phenotypic variance, respectively. We then applied a 
regression-based approach28 to adjust for LD between SNPs. The estimates of variance 
explained after LD-adjustment were slightly higher than those without adjustment, and the 
ratio of between the estimates with and without LD-adjustment was consistently ~1.05 
regardless of the window size (Supplementary Fig. 6a). However, the difference is small.
We then sought to investigate whether or not there is an enrichment of additional association 
signals at the top associated loci. We varied the window size from 20Kb to 50Kb, 100Kb, 
150Kb, 200Kb, 300Kb, 400Kb, 500Kb, 750Kb and 1Mb, and fitted a two-component model 
in GCTA-GREML analysis, with the first component being the top associated SNPs and the 
second component being the rest of SNPs within the window. We found that the per-SNP 
variance explained excluding the top SNPs (variance explained by the second component 
divided by the number of SNPs included in this component) decreased with the size of 
window (Supplementary Fig. 6b), implying that SNPs in closer physical proximity to the top 
associated SNPs tend to explain disproportionally more variance.
Enrichment of associated SNPs in ENCODE regions, loci containing OMIM genes, eQTLs 
and nsSNPs
To identify putative causal variants among the height-associated markers, we explored 
whether the height-associated SNPs were in strong LD (r2>0.8) with non-synonymous 
coding variants in 1000 Genomes Project CEU Phase 1 data, showed an effect on whole 
blood gene expression levels, were located within ENCODE-annotated regions, were within 
loci harboring monogenic growth genes, or had previously been associated with other 
complex traits in NHGRI GWAS catalog (P<5×10−8) (Supplementary Tables 7-11). To 
estimate the empirical assessment of enrichment for listed features we used 10,000 
permutations of random sets of SNPs matched to the pruned (LD r2>0.1) 628 height-
associated SNPs by the number of nearby genes (within a distance of LD r2>0.5), physical 
distance to nearest gene, and minor allele frequency.
Enrichment of genes in associated loci in known and novel pathways
Data-Driven Expression-Prioritized Integration for Complex Traits (DEPICT) 
analysis—The DEPICT method (T.H.P. et al., unpublished data; see Geller et al.29 for an 
earlier application of DEPICT) relies on pre-computed predictions of gene function based on 
a heterogeneous panel of 77,840 expression arrays (Fehrmann et al., manuscript in review; 
ref. 30), 5,984 molecular pathways (based on 169,810 high-confidence experimentally 
derived protein-protein interactions31), 2,473 phenotypic gene sets (based on 211,882 gene-
phenotype pairs from the Mouse Genetics Initiative (see URLs)), 737 Reactome pathways32, 
5,083 Gene Ontology terms14, and 184 KEGG pathways33. The method leverages these 
predictions to extend the functional annotations of genes, including genes that previously 
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had only a few or no functional annotations. DEPICT facilitates the analysis of GWAS data 
by (1) assessing whether genes in associated loci are enriched in tissue-specific expression, 
(2) identifying reconstituted gene sets that are enriched in genes from associated loci, and 
(3) systematically identifying the most likely causal gene(s) at a given locus (see 
Supplementary Note for a more detailed description of DEPICT). In order to run DEPICT, 
we first clumped the summary statistics from the meta-analysis using 500kb flanking 
regions, r2>0.1, and excluded SNPs with P≥5×10−8, which resulted in 628 SNPs. We then 
mapped genes to each of the 628 best-associated SNPs. For a given SNP, this was 
accomplished by including all genes that resided within LD r2>0.5 boundaries of that SNP, 
and always including the nearest gene, to its locus gene set. We used a locus definition that 
was calibrated using the GWAS data for height levels presented in this paper and optimized 
capture of known monogenic genes for those traits. We merged overlapping loci, and 
excluded loci that mapped near or within the major histocompatibility complex locus 
(chromosome 6, location: 20 to 40 Mb), which resulted in a list of 566 non-overlapping loci 
that were used as input to DEPICT. HapMap Project Phase II CEU genotype data was used 
for all LD calculations.
GRAIL and MAGENTA analysis—The GRAIL14 algorithm was run using the LD 
pruned (r2>0.1) 628 SNPs without correcting for gene size, and using text-mining data up to 
December 2006 (default setting). MAGENTA13 was run with the single genomic control 
adjusted summary statistics as input using default settings and excluding the HLA region.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Regional association plots for loci with multiple association signals
Panels a to d highlight examples of multiple signals after approximate conditional joint 
multiple-SNP analysis GCTA-COJO analysis. SNPs are shaded and shaped based on the 
index SNP with which they are in strongest LD (r2>0.4). Panels a-c show the majority of 
signals clustering in and around a single gene (ACAN, ADAMTS17, PTCH1, respectively) 
whereas panel d shows the multiple signals clustering through proximity.
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Figure 2. Quantifying the variance explained by height associated SNPs at different levels of 
significance
The SNPs were selected from the approximate conditional and joint multiple SNPs 
association analysis using GCTA-COJO analysis with the target cohort being excluded from 
the meta-analysis. a, b, c, Partitioning the variance in the SNP-derived genetic predictor 
using a within-family analysis. The SNP-based predictor was adjusted by the first 20 PCs. 
The four variance-covariance components Vg, Ve, Cg and Ce are defined in Online Methods. 
d, Accuracy of predicting phenotype by the genetic predictor in unrelated individuals. The 
prediction R2 shown on the y-axis is the squared correlation between phenotype and 
predictor. The SNP-based predictor was adjusted by the first 20 PCs. The solid line is the 
average prediction R2 weighted by sample size over the five cohorts. The dashed line is the 
prediction accuracy inferred from the within-family prediction analysis (Equation 19 in 
Online Methods). e, The variance explained by the SNPs was estimated by the whole-
genome estimation method in GCTA. The phenotype was adjusted by the first 20 PCs. Each 
error bar represents the standard error of the estimate. The estimates from all the five cohorts 
(B-PROOF, FRAM, QIMR, TwinGene and WTCCC-T2D) were averaged by the inverse-
variance approach. The dashed line is the variance explained inferred from the within-family 
prediction analysis. In panels d and e, the number shown in each column is the number of 
SNPs used in the analysis.
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Figure 3. Tissue enrichment combined with pruned gene set network
Genes within genome-wide significant height associated loci enriched for several relevant 
tissue annotations as well as gene sets. a, Genes in associated loci tended to be highly 
expressed in tissues related to chondrocytes and osteoblasts (cartilage, joints, and spine), and 
other musculoskeletal, cardiovascular and endocrine tissue-types. The analysis was 
conducted based on the DEPICT method and 37,427 human microarray samples. Tissue 
annotations are sorted by physiological system and significance. Significantly enriched 
(FDR<0.05) tissues are color-coded in black. b, Significantly enriched reconstituted gene 
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sets (P-value<1×10−11, FDR<1×10−5) identified by DEPICT. Nodes represent reconstituted 
gene sets and are color-coded by statistical significance. Edge thickness between nodes is 
proportional to degree of gene overlap as measured by the Jaccard index. Nodes with gene 
overlap greater than 25% were collapsed into single meta nodes and marked by blue borders. 
c, reconstituted gene sets comprised by the Chordate Embryonic Development meta node, 
which represented several gene sets relevant to human height (e.g. ossification, embryonic 
skeletal system development, and limb development).
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Table 2
Comparison of prioritized variants, loci, biology and variance explained from GWASs on 
human stature with 130,000 individuals (previously published in Lango Allen et al., 2010) 
and with 250,000 individuals (this paper).
Height GWAS with 130,000 samples (Lango 
Allen et al., Yang et al)* Height GWAS with 253,288 samples
SNP based comparisons
GWAS significant SNPS 199 697
Genomic loci# (+/− 1Mb) 180 423
Loci# with multiple signals 19 147
Secondary associations in loci# 19 273
Biological annotation (DEPICT at FDR < 0.05)
Prioritized genes 92 649
Loci& with prioritized gene 74 (43%) 422 (75%)
Pruned gene sets and protein-protein complexes% 813 2,330
Tissues and cell-types 5 43
Variance explained
GWAS significant SNPs 10% 16%
Deep list of SNPs at 1×10−3 13% 29%
All common SNPs 45%** 50%
Heritability explained
GWAS significant SNPs 12.5% 20%
Deep list of SNPs at 1×10−3 16% 36%
All common SNPs 56%** 62.5%
*Counts, numbers and estimates for Lango Allen et al. are taken from respective publication.
#Genomic loci defined by distance: +/− 1Mb from index height SNP
&Genomic loci defined by LD: r2 > 0.5 from index height SNP
%After clumping of similar gene sets and pathways
**
Yang et al. Nat Genet 42, 565-9 (2010).
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Table 3
Significantly prioritized novel human growth associated genes
The table lists 20 genes prioritized by DEPICT. Genes are ranked by the number of lines of supporting 
evidence and the DEPICT P-value (Supplementary Table 16). Because 20 of the 30 top-ranked genes were in 
a curated list of genes known to cause syndromes of skeletal12, these “OMIM genes” are not shown here. The 
top fifteen genes with prior literature support (based on GRAIL) are shown, followed by the top five novel 
genes. Each gene is accompanied by the significantly enriched reconstituted gene sets in which it appears in 
(DEPICT gene set enrichment analysis). Abbreviations; (GO – Gene Ontology; MP – Mice Phenotypes from 
Mouse Genome Informatics database; InWeb – protein-protein interaction complexes; KEGG and 
REACTOME databases).
Locus (height SNP) Gene symbol New locus Prioritization P-value
Levels of 
biological 
annotation
Top ranking reconstituted gene sets
Genes with prior literature support (GRAIL)
rs10748128 FRS2 N 1.0×10−16 7
PI 3K cascade (REACTOME, 
P=6.2×10−13); Chronic Myeloid Leukemia 
(KEGG, P=1.6×10−12); Response To 
Fibroblast Growth Factor Stimulus (GO, 
P=5.4×10−11);
rs2166898 GLI2 Y 4.4×10−16 7
Growth Factor Binding (GO, 
P=2.6×10−14); Regulation Of Osteoblast 
Differentiation (GO, P=2.3×10−11); WNT-
Protein Binding (GO, P=1.9×10−12)
rs526896-rs9327705 TBX4 N 9.9×10−9 7
Short Mandible (MP, P=3.3×10−19); 
Respiratory System Development (GO, 
P=3.1×10−17); Abnormal Ulna 
Morphology (MP, P=1.9×10−15)
rs16860216 SOX8 N 0.016 7
Small Thoracic Cage (MP, P=6.9×10−14); 
Short Ribs (MP, P=2.7×10−8); Short 
Sternum (MP, P=6.5×10−7)
rs1199734 LATS2 Y 1.0×10−16 6
Partial Lethality Throughout Fetal Growth 
And Development (MP, P=1.2×10−18); 
Growth Factor Binding (GO, 
P=2.6×10−14); TGFB1 protein complex 
(InWeb, P=6.3×10−12)
rs12323101 PDS5B N 1.0×10−16 6
Chromatin Binding (GO, P=6.4×10−17); 
Nuclear Hormone Receptor Binding (GO, 
P=2.4×10−12); RBBP4 protein complex 
(InWeb, P=1.3×10−11); WNT16 protein 
complex (InWeb, P=1.9×10−8)
rs6746356 SP3 Y 1.0×10−16 6
BCOR protein complex (InWeb, 
P=2.7×10−17); AFF2 protein complex 
(InWeb, P=4.5×10−7); Intracellular Steroid 
Hormone Receptor Signaling Pathway 
(GO, P=9.0×10−6)
rs3923086 AXIN2 Y 2.2×10−16 6
Signaling By Transforming Growth Factor 
Beta (KEGG,P=3.8×10−15); WNT 
Receptor Signaling Pathway (GO, 
P=6.9×10−14); Polydactyly (MP, 
P=1.5×10−10)
rs3790086 LTBP1 N 1.3×10−13 6
Abnormal Skeleton Morphology (MP, 
P=1.1×10−15); TGF Beta Signaling 
Pathway (KEGG, P=3.8×10−15); Growth 
Factor Binding (GO, P=2.6×10−14)
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Locus (height SNP) Gene symbol New locus Prioritization P-value
Levels of 
biological 
annotation
Top ranking reconstituted gene sets
rs2034172 WNT5A Y 4.3×10−13 6
Partial Lethality Throughout Fetal Growth 
And Development (MP, P=1.2×10−18); 
Tissue Morphogenesis (GO, 
P=4.1×10−20); Abnormal Skeleton 
Morphology (MP, P=1.1×10−15)
rs3915129 CTNNB1 Y 3.5×10−12 6
AR protein complex (InWeb, 
P=8.9×10−17); TCEB1 protein complex 
(InWeb, P=1.5×10−11); GTF2I protein 
complex (InWeb, P=4.6×10−11)
rs12330322 BMP2 N 5.6×10−10 6
Transcription Factor Binding (GO, 
P=4.7×10−26); Complete Embryonic 
Lethality During Organogenesis (MP, 
P=4.9×10−21); Short Mandible (MP, 
P=3.3×10−19)
rs10958476-rs6999671 BMP6 N 2.9×10−8 6
Small Basisphenoid Bone (MP, 
P=8.9×10−17); TGF Beta Signaling 
Pathway (KEGG, P=3.8×10−15); Growth 
Factor Binding (GO, P=2.6×10−14)
rs564914 SOX5 Y 4.6×10−7 6
Disproportionate Dwarf (MP, 
P=1.8×10−13); Abnormal Cartilage 
Morphology (MP, P=1.9×10−13); Short 
Limbs (MP, P=2.8×10−13)
rs17807185 WNT4 Y 4.6×10−7 6
Morphogenesis Of An Epithelium (GO, 
P=2.3×10−17); Gland Development (GO, 
P=5.4×10−16); Basal Cell Carcinoma 
(KEGG, P=1.5×10−12)
Novel genes without prior evidence
rs8042424 CHSY1 N 1.0×10−16 7
Abnormal Cartilage Morphology (MP, 
P=1.9×10−13); Abnormal Bone 
Ossification (MP, P=2.1×10−12); Signaling 
by Transforming Growth Factor Beta 
(REACTOME, P=5.9×10−9)
rs7652177 FNDC3B N 1.0×10−16 5
Abnormal Spongiotrophoblast Layer 
Morphology (MP, P=3.2×10−16); 
Decreased Length Of Long Bones (MP, 
P=2.7×10−12); ITGB1 protein complex 
(InWeb, P=5.2×10−8)
rs7284476 TRIOBP Y 1.0×10−16 5
Negative Regulation Of Cell Proliferation 
(GO, P=4.3×10−17); Abnormal Vitelline 
Vasculature Morphology (MP, 
P=1.7×10−15); Beta-Catenin Binding (GO, 
P=3.0×10−5)
rs2149163-rs3927536 BNC2 N 1.0×10−16 5
Short Ulna (MP, P=4.7×10−13); Abnormal 
Joint Morphology (MP, P=8.6×10−11); 
Regulation Of Chondrocyte 
Differentiation (GO, P=2.9×10−9)
rs3790086 WWP2 Y 1.0×10−16 5
Cartilage Development (GO, 
P=2.0×10−19); Chondrocyte 
Differentiation (GO, P=3.0×10−15); 
Signaling By Platelet-Derived Growth 
Factor (REACTOME, P=4.8×10−10)
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